WeTrials
Completed

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

What is this study?

This study is testing how well a new medication called LY3841136 works, either alone or mixed with Tirzepatide, to help adults manage their weight. It is especially designed for people who also have Type 2 Diabetes, which affects how the body handles sugar.

Who can participate?

You might be able to join if you are an adult with overweight or obesity and have Type 2 Diabetes that is managed with diet and exercise or certain stable medications. However, people with specific heart conditions or a history of dangerous blood sugar drops cannot take part.

What will happen?

Participants will take either the study medication, a combination therapy, or a placebo, which looks like the medicine but has no active ingredients. The entire study lasts for about 64 weeks to check on safety and how well the treatment works.

Where and when?

The study locations are in Chandler, Phoenix, and Scottsdale, Arizona, in the United States. Please note that this study has already been completed.

Key Points
  • 1Tests new weight management medications for adults with Type 2 Diabetes
  • 2Study lasts for approximately 64 weeks
  • 3Locations included multiple cities in Arizona, United States

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
ObesityOverweight

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.